P

Pedestal Health

Sponsors real-world evidence for drug development

Principal Data Scientist

Full-Time
No salary listed
Expert
Master's, PhD
Research Triangle Park, Durham, NC, USA
HybridThree days per week in the office.
AI & Machine LearningApplied Machine Learning

About the job

Requirements
  • An MS or PhD in data science, statistics, computer science, computational biology, or a related quantitative field, or equivalent practical experience.
  • Experience working with real-world healthcare data, including electronic health records, claims, or registry data, and familiarity with its structural and quality challenges.
  • A track record of building internal tools, platforms, or analytic products used by others and owning them through multiple versions, rather than solely delivering analyses.
  • Strong programming ability in Python and SQL, with experience in a cloud data warehouse environment such as Snowflake.
  • Demonstrated end-to-end ownership of a data quality, testing, or observability system, beyond authoring individual checks.
  • Practical experience building with large language models beyond prototyping, including prompt and workflow design and a clear approach to evaluating whether an LLM-based system is working.
  • Comfort working with raw, messy, poorly documented source data, and the curiosity and persistence to determine what it contains.
  • Experience working cross-functionally with product and engineering partners, and the ability to advocate constructively for technical priorities when priorities compete.
  • Clear written and verbal communication, including the ability to explain a method's limitations as readily as its results.
  • Interest in growing into technical leadership, including mentoring and reviewing other data scientists' work.
Responsibilities
  • Build, maintain, and improve AI-powered tooling for reliable, repeatable commercial cohort counts and feasibility work.
  • Extend AI tooling to recurring analytics, including generating and reviewing analysis code and supporting protocol and analysis plan development.
  • Gather requirements from internal tool users and iterate based on their feedback.
  • Define testing against known-correct results, validate updates before release, monitor performance as underlying data evolves, and determine where human review remains mandatory.
  • Scale adoption of tooling through documentation, training, onboarding, and hands-on enablement.
  • Define guardrails for AI use in client-facing work, including permitted data, review processes, and provenance recording.
  • Redesign data quality checks so assessing new sources or refreshed schemas does not require redoing work each time.
  • Automate data quality assessment and maintain durable records of checks, findings, and resolutions.
  • Determine where AI and agentic methods provide leverage and where deterministic, reproducible checking should remain foundational.
  • Define measures of data quality system effectiveness, including whether recipients trust and act on quality signals.
  • Partner with Engineering on pipeline integration, orchestration, and monitoring.
  • Partner with Product, Engineering, Medical Science, Clinical Operations, and Commercial teams.
  • Advocate for the quality and validation work required by AI-assisted products in roadmap and prioritization discussions.
  • Track developments in AI tooling and methods and incorporate useful approaches into standards, training, and tooling.
  • Provide technical oversight, code review, and mentorship to other data scientists, and establish standards for their work.
  • Help grow the data science group as it expands.

About the company

Pedestal Health focuses on real-world evidence (RWE) by designing and sponsoring disease-specific patient cohorts to generate regulatory-grade data and insights for drug development. It builds customizable RWE communities that provide researchers with high-quality data, enabling regulatory submissions and informed decision-making for pharmaceutical companies, regulators, and healthcare providers. The company offers tailored data solutions, consulting services, and biospecimen samples, funded through partnerships and service contracts. Its main differentiator is assembling end-to-end, disease-focused RWE networks and supplying both data and biological materials, rather than just aggregating datasets. The goal is to help clients accelerate and improve drug development and regulatory processes by delivering robust, real-world insights grounded in well-characterized patient cohorts.

Company Size

51-200

Company Stage

Seed

Total Funding

$2.8M

Headquarters

Durham, North Carolina

Founded

2015

Get referred to Pedestal Health

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • April 2026 leadership hires in commercial, delivery, and finance support scaling.
  • 2026 publications for Merck, Amgen, and AbbVie validate commercial demand.
  • Rebrand on May 18, 2026 signals broader positioning beyond Target RWE's legacy brand.

What critics are saying

  • Narrow disease focus makes MASH, PBC, PSC, and IBD pipeline concentration severe.
  • Competing CROs and data vendors can replicate single-disease evidence services by 2027.
  • If major pharma programs shift to internal RWE teams, Pedestal Health loses core revenue.

What makes Pedestal Health unique

  • Pedestal Health built decade-long longitudinal cohorts in hepatology, dermatology, and gastroenterology.
  • Its hybrid model combines EHR, prospective collection, biomarkers, imaging, and external controls.
  • Highlander Health acquired Target RWE in January 2025, backing regulatory-grade evidence generation.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options
  • Comprehensive health, dental, and vision for you and your family
  • 401(k) with company match
  • Generous PTO and company holidays
  • Paid parental leave

Growth & Insights and Company News

6 month growth

4%

1 year growth

1%

2 year growth

0%
Business Wire
Apr 2nd, 2026
Target RWE appoints leadership across delivery, finance and commercial to scale evidence generation operations

Target RWE, a clinical evidence generation company, has announced three senior leadership appointments to support its growth. Steve Swanson has been promoted to chief commercial officer, leading commercial strategy and partnerships with biopharma and healthcare companies. Emily Akin joins as head of delivery, overseeing clinical operations and data curation. She previously led Flatiron Trials and Research Network at Flatiron Health. Ashley Pierce has been appointed head of finance, bringing experience from Syneos Health and Capitol Broadcasting Company. The company, backed by investment firm Highlander Health, specialises in real-world evidence generation designed to meet regulatory standards for drug development. The leadership team collectively brings nearly 70 years of experience across life sciences and healthcare to advance Target RWE's evidence generation and clinical trial capabilities.

Business Wire
Nov 6th, 2025
Target RWE Announces Upcoming Presentations at AASLD - The Liver Meeting 2025

Target RWE announces upcoming presentations at AASLD - The Liver Meeting 2025. DURHAM, N.C.-(BUSINESS WIRE)-Target RWE, a leader in advancing modern evidence generation for complex clinical and regulatory challenges, today announced it will have multiple presentations focused on the testing and related outcomes of patients with metabolic dysfunction-associated steatotic liver disease (MASLD) at the upcoming American Association for the Study of Liver Diseases (AASLD) The Liver Meeting(R) 2025, taking place November 7-11, 2025 in Washington, D.C. Poster Number: 2114 Date and Time: November 8, 2025, 8:00 am - 5:00 pm ET Presentation Title: Changes in the Fibrosis-4 (FIB-4) score accurately reflects the disease trajectory of metabolic dysfunction associated steatotic liver disease. Presenter: Vinay Jahagirdar, MD, GI Fellow, Division of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University Health System, Richmond, Virginia. Summary: A FIB-4 score of 1.3-2.6 reflects an intermediate risk stratum of MASLD where secondary tests with vibration-controlled transient elastography (VCTE) repeat testing is recommended. VCTE is not, however, universally available and the utility of repeat FIB-4 testing to assess changes in clinical status in MASLD is not known. The study authors hypothesized that changes in FIB-4 will coordinately track the risk of clinical outcomes in MASLD. The aim of this study was to define the performance of changes in FIB-4 as a disease-monitoring test in MASLD. The authors concluded that changes in FIB-4 predict future risk of adverse health outcomes independent of age and changes in BMI. Thus, in this intermediate risk FIB-4 category especially with T2DM, repeat testing and change in FIB-4 can be used to assess prognosis and disease trajectory. Poster Number: 2618 Date and Time: November 8, 2025, 8:00 am - 5:00 pm ET Presentation Title: Clinical characteristics and outcomes of patients with presumed MASLD who meet MetALD criteria in the TARGET-NASH cohort Presenter: A. Sidney Barritt IV, MD, MSCR, Professor of Medicine, Director of Hepatology, and Transplant Hepatology Program Director in the Division of Gastroenterology and Hepatology, University of North Carolina School of Medicine, Chapel Hill. Summary: Many patients with hepatic steatosis are presumed to have MASLD due to comorbid cardiovascular (CV) risk factors. However, alcohol use may not be accurately quantified by providers or fully disclosed by some patients. The characteristics and outcomes of patients with MASLD and increased alcohol intake - metabolic dysfunction and alcohol-related liver disease (MetALD) - are unknown. The study sought to describe these patients in the TARGET-NASH cohort and found that despite younger age and fewer metabolic risk factors, MetALD patients suffered a similar number of incident, major adverse cardiovascular(MACE) events on a faster timeframe compared with traditional MASLD patients. About Target RWE Target RWE generates real-world evidence (RWE) that informs strategic decisions across the drug development lifecycle. Our unique combination of clinical, analytical and technical expertise enables comprehensive insight generation from complete retrospective and prospective longitudinal patient journeys, with unparalleled scale and accuracy. Visit our website to learn more: https://targetrwe.com/

Newswise
May 9th, 2025
Target RWE at EASL 2025: Advancing HCC, MASH & PBC Research

Target RWE unveiled findings on MASH and HCC and contributed expert leadership to the highly anticipated PBC Consensus Conference on May 6th.

PR Newswire
Mar 7th, 2025
Patient-Centric Data Capture Fuels Growth Of Target Rwe Longitudinal, Real-World Dermatology Studies

Insights into Hidradenitis Suppurativa from Target RWE Featured in Posters at AAD 2025 DURHAM, N.C., March 7, 2025 /PRNewswire/ -- Real-world evidence (RWE) leader, Target RWE, announced updates from its longitudinal dermatology study of more than 7,000 enrolled patients with two poster presentations on patients with Hidradenitis Suppurativa (HS) at the American Academy of Dermatology (AAD) annual meeting in Orlando, FL, March 7-11, 2025

Business Wire
Jan 8th, 2025
Highlander Health Announces Inaugural Investment of Target RWE

Highlander Health today announced the acquisition of Target RWE from existing investors, including 22C Capital.